AllSci News
Johnson & Johnson's lumateperone ranks highest in adjunctive major depressive disorder network meta-analysis
Johnson & Johnson (NYSE: JNJ) reported that lumateperone (Caplyta) ranked highest across four efficacy measures in a network meta-analysis comparing...
Cabaletta Bio raises USD 150m via share offering
Cabaletta Bio (Nasdaq: CABA), a Philadelphia-based clinical-stage cell therapy company, announced the pricing of an underwritten public offering to raise...
Cue Biopharma raises USD 30m in private placement PIPE financing
Boston-based Cue Biopharma, Inc. (Nasdaq: CUE) announced a USD 30 million PIPE financing on April 30, 2026, with proceeds directed toward advancing its...
Climb Bio raises USD 110m in private placement for immune-disease pipeline
Wellesley Hills, Massachusetts-based Climb Bio, Inc. (Nasdaq: CLYM) announced a USD 110.0 million private placement to fund continued clinical development...
Rein Therapeutics raises USD 50m in public share offering
US-based Rein Therapeutics (Nasdaq: RNTX) announced an underwritten public offering of common stock priced at USD 50 million, with proceeds designated to...
Aura Biosciences raises USD 260.3m in public offering of common stock
Aura Biosciences (Nasdaq: AURA) announced the pricing of an underwritten public offering to fund registration-enabling activities for its lead asset,...
Ovarian Cancer Canada hands USD 725k to natural killer cell immunotherapy program at Dalhousie University
Ovarian Cancer Canada has announced USD 725,000 in ovarian cancer treatment funding for a natural killer (NK) cell immunotherapy program led by Dr. Jeanette...
Oncolytics' pelareorep shows durable responses in second-line KRAS-mutant colorectal cancer
Oncolytics Biotech (Nasdaq: ONCY) reported a median duration of response of 19.5 months for pelareorep in combination with bevacizumab and FOLFIRI in...
Atsena's Atsn-201 achieves foveal schisis closure in X-linked retinoschisis Phase I/II/III trial
Atsena Therapeutics reported interim six-month data from Part B of the Phase I/II/III LIGHTHOUSE trial evaluating ATSN-201 in X-linked retinoschisis,...
Atossa Therapeutics wins FDA Rare Pediatric Disease designation for Z-endoxifen in McCune-Albright Syndrome
Atossa Therapeutics (Nasdaq: ATOS) announced receipt of an FDA Rare Pediatric Disease (RPD) designation for (Z)-endoxifen in the treatment of McCune-Albright Syndrome…
Oruka Therapeutics raises USD 700.4m in underwritten public offering
Menlo Park, California-based Oruka Therapeutics, Inc. (Nasdaq: ORKA) announced the pricing of an upsized underwritten public offering on April 28, 2026,...
Windward Bio closes USD 165m financing for long-acting immunology therapies
Basel-based Windward Bio has closed a USD 165 million crossover financing round to advance its pipeline of long-acting antibody therapies targeting serious...
BioCryst grants Neopharmed Gentili European rights to navenibart for hereditary angioedema, USD 345m deal
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary...
Gyre Therapeutics completes USD 300m acquisition of Cullgen to create integrated US-China biotech company
Gyre Therapeutics (Nasdaq: GYRE) has completed the acquisition of Cullgen Inc., a privately held, clinical-stage biopharmaceutical company focused on...
FDA approves ADMA Biologics’ Asceniv for pediatric immune compromised patients aged two and older
ADMA Biologics announced US FDA approval of a supplemental Biologics License Application for Asceniv (immune globulin intravenous, human – slra 10% liquid),…
The AllSci Brief
Systematic R&D and deal news. Daily.